Merck’s newly approved drug for Pulmonary Arterial Hypertension (PAH), known as Winrevair or sotatercept during its development phase, marks a significant step forward in treating this potentially life-threatening lung and heart disorder. Unlike the current roster of PAH treatments which primarily alleviate symptoms, Winrevair targets the underlying cause behind the malfunctioning signaling pathway that precipitates symptoms.This approval from the FDA is a first-in-class for such an approach.
PAH, a rarer strain of hypertension, detrimentally affects the arteries that facilitate blood transport from the right side of the heart to the lungs. Narrowing of these arteries slow blood flow and exert substantial pressure on the heart. Over time, this can culminate in heart failure. Sotatercept intercepts and neutralizes the overactive cell signaling balance believed to cause cell proliferation and, in turn, the contraction of pulmonary vessels.
In a phase 3 clinical trial that measured the drug’s effectiveness through a cardiovascular walk test, the results documented a significant improvement in patient walk distance and a dramatic reduction in death probability. Post-data publication in The New England Journal of Medicine last year further solidified its effectiveness.
Merck added Winrevair to its product line after a hefty $11.5 billion acquisition of Acceleron Pharma in 2021. Given the impending decline in revenue due to the expiration of patents for Keytruda, Merck’s top-selling cancer immunotherapy, the uptake of Winrevair helps diversify and secure its portfolio.
Slated to hit the market by April end, Winrevair presents an expensive treatment option with a cost exceeding $242,000 annually. Nonetheless, Merck assures that the patients’ out-of-pocket cost, which will depend on their insurance plan’s specifics, may comprise an out-of-pocket maximum. The drug is also under regulatory review in Europe, with ongoing clinical trials set to potentially broaden its usage. In the backdrop, Merck continues its exploration of more PAH drugs, now testing an inhalable medication and working alongside other players like Aerovate Therapeutics, Gossamer Bio, and Keros Therapeutics.
Read more about Winrevair’s impact and potential in this comprehensive report by MedCity News.